BridgeBio Financial Statements (BBIO)
|
|
|
|
Report date
|
|
|
25.02.2022 |
23.02.2023 |
22.02.2024 |
20.02.2025 |
24.02.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
69.7 |
77.6 |
9.30 |
221.9 |
502.1 |
|
580.0 |
|
Operating Income, bln rub |
|
|
-576.6 |
-512.2 |
-607.4 |
-593.0 |
-569.1 |
|
-570.7 |
|
EBITDA, bln rub |
? |
|
-533.8 |
-397.4 |
-565.5 |
-436.8 |
-672.9 |
|
-601.1 |
|
Net profit, bln rub |
? |
|
-562.5 |
-481.2 |
-643.2 |
-535.8 |
-729.3 |
|
-725.9 |
|
|
OCF, bln rub |
? |
|
-497.9 |
-419.5 |
-527.7 |
-520.7 |
-445.9 |
|
-444.0 |
|
CAPEX, bln rub |
? |
|
48.2 |
6.32 |
1.31 |
0.933 |
1.10 |
|
10.2 |
|
FCF, bln rub |
? |
|
-546.2 |
-425.8 |
-529.0 |
-521.7 |
-447.0 |
|
-454.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
643.2 |
586.4 |
614.2 |
811.0 |
1 043 |
|
1 115 |
|
Cost of production, bln rub |
|
|
3.11 |
3.43 |
2.45 |
3.88 |
28.3 |
|
36.1 |
|
R&D, bln rub |
|
|
451.0 |
399.5 |
455.7 |
506.5 |
477.5 |
|
492.7 |
|
Interest expenses, bln rub |
|
|
46.8 |
80.4 |
81.3 |
99.3 |
53.1 |
|
114.2 |
|
|
Assets, bln rub |
|
|
1 013 |
623.0 |
546.4 |
919.3 |
936.0 |
|
1 371 |
|
Net Assets, bln rub |
? |
|
-870.4 |
-1 255 |
-1 354 |
-1 468 |
-2 077 |
|
-2 269 |
|
Debt, bln rub |
|
|
1 726 |
1 724 |
1 740 |
1 731 |
2 729 |
|
3 385 |
|
Cash, bln rub |
|
|
836.7 |
471.9 |
434.9 |
681.1 |
587.5 |
|
940.2 |
|
Net debt, bln rub |
|
|
889.5 |
1 252 |
1 305 |
1 049 |
2 141 |
|
2 445 |
|
|
Ordinary share price, rub |
|
|
16.7 |
7.62 |
40.4 |
27.4 |
76.5 |
|
26.9 |
|
Number of ordinary shares, mln |
|
|
144.4 |
147.5 |
162.8 |
186.1 |
197.2 |
|
194.8 |
|
|
Market cap, bln rub |
|
|
2 408 |
1 124 |
6 572 |
5 106 |
15 087 |
|
5 244 |
|
EV, bln rub |
? |
|
3 297 |
2 375 |
7 877 |
6 155 |
17 228 |
|
7 688 |
|
Book value, bln rub |
|
|
-915 |
-1 283 |
-1 381 |
-1 492 |
-2 105 |
|
-2 296 |
|
|
EPS, rub |
? |
|
-3.90 |
-3.26 |
-3.95 |
-2.88 |
-3.70 |
|
-3.73 |
|
FCF/share, rub |
|
|
-3.78 |
-2.89 |
-3.25 |
-2.80 |
-2.27 |
|
-2.33 |
|
BV/share, rub |
|
|
-6.34 |
-8.70 |
-8.48 |
-8.02 |
-10.7 |
|
-11.8 |
|
|
EBITDA margin, % |
? |
|
-765.7% |
-511.9% |
-6 078% |
-196.9% |
-134.0% |
|
-103.6% |
|
Net margin, % |
? |
|
-806.9% |
-619.7% |
-6 914% |
-241.4% |
-145.3% |
|
-125.2% |
|
FCF yield, % |
? |
|
-22.7% |
-37.9% |
-8.05% |
-10.2% |
-2.96% |
|
-8.66% |
|
ROE, % |
? |
|
64.6% |
38.4% |
47.5% |
36.5% |
35.1% |
|
32.0% |
|
ROA, % |
? |
|
-55.5% |
-77.2% |
-117.7% |
-58.3% |
-77.9% |
|
-52.9% |
|
|
P/E |
? |
|
-4.28 |
-2.34 |
-10.2 |
-9.53 |
-20.7 |
|
-7.22 |
|
P/FCF |
|
|
-4.41 |
-2.64 |
-12.4 |
-9.79 |
-33.8 |
|
-11.5 |
|
P/S |
? |
|
34.5 |
14.5 |
706.4 |
23.0 |
30.0 |
|
9.04 |
|
P/BV |
? |
|
-2.63 |
-0.88 |
-4.76 |
-3.42 |
-7.17 |
|
-2.28 |
|
EV/EBITDA |
? |
|
-6.18 |
-5.98 |
-13.9 |
-14.1 |
-25.6 |
|
-12.8 |
|
Debt/EBITDA |
|
|
-1.67 |
-3.15 |
-2.31 |
-2.40 |
-3.18 |
|
-4.07 |
|
|
R&D/CAPEX, % |
|
|
934.8% |
6 320% |
34 894% |
54 283% |
43 531% |
|
4 847% |
|
|
CAPEX/Revenue, % |
|
|
69.2% |
8.14% |
14.0% |
0.42% |
0.22% |
|
1.75% |
|
| BridgeBio shareholders |
